Form 4: Mirum Pharmaceuticals CEO Acquires Shares Through Employee Stock Purchase Plan
SEC Form 4 Filing
Christopher Peetz, CEO of Mirum Pharmaceuticals, acquired 817 shares of common stock through the company's Employee Stock Purchase Plan on May 10, 2024.
Summary
- Christopher Peetz, the CEO of Mirum Pharmaceuticals, acquired 817 shares of common stock on May 10, 2024.
- The acquisition was made through the company's Employee Stock Purchase Plan.
- The price per share was $21.046.
- Following the transaction, Peetz directly owns 92,770 shares of common stock.
- He also indirectly owns 208,570 shares through The Peetz Family Trust.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a routine transaction (stock purchase by the CEO through an employee plan). It doesn't contain any information that would significantly sway investor sentiment positively or negatively.
Positives
- The CEO's participation in the Employee Stock Purchase Plan could be seen as a positive signal, indicating confidence in the company's future.
Industry Context
This type of transaction is common for executives who participate in employee stock purchase plans. It's a way for them to increase their ownership stake in the company.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it shows the CEO's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 05/10/2024 | Date of the stock acquisition by Christopher Peetz. |
| 05/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.